Pharmacogenomic Variability
Genetic differences in CYP450 enzymes and serotonin transporter genes change how you respond to antidepressants and increase the risk of poor response or side effects.
Standard antidepressants work largely by increasing serotonin, norepinephrine or dopamine signaling in the brain. In treatment-resistant depression, this approach is not enough on its own. Patients with TRD often have differences in how their bodies metabolize medication, in neuroplasticity and neural circuit activity, or in underlying medical and psychological factors that keep depressive symptoms locked in. The NIMH overview of depression outlines how genetic, biological and environmental factors interact to produce persistent depressive episodes.
One of the most overlooked drivers is pharmacogenomic variability. Genes such as CYP2D6, CYP2C19 and others influence how quickly antidepressants are metabolized and how strongly they act at their targets. Genomind gene testing for medication guidance uses a simple cheek swab to identify these variations so that prescribing is informed by your DNA, not just trial and error.
Other contributors include unrecognized bipolar features, thyroid disease, sleep apnea, chronic pain, substance use, hormonal shifts and ongoing trauma or psychosocial stress. When any of these factors are missed, even the right medication may not produce the response you expect, which is why a careful re-evaluation is the first step in our approach.
